Literature DB >> 27507775

The Clinical Significance of N-terminal Pro-brain Natriuretic Peptide in Detecting the Residual Cardiovascular Risk in Hypertension and Other Clinical Conditions and in Predicting Future Cardiovascular Events.

Steven G Chrysant1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27507775      PMCID: PMC8031586          DOI: 10.1111/jch.12785

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  15 in total

1.  N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population.

Authors:  Gerard C M Linssen; Stephan J L Bakker; Adriaan A Voors; Ron T Gansevoort; Hans L Hillege; Paul E de Jong; Dirk J van Veldhuisen; Rijk O B Gans; Dick de Zeeuw
Journal:  Eur Heart J       Date:  2009-10-23       Impact factor: 29.983

2.  N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension.

Authors:  Vinciane Paget; Liliana Legedz; Nathalie Gaudebout; Nicolas Girerd; Giampiero Bricca; Hugues Milon; Madeleine Vincent; Pierre Lantelme
Journal:  Hypertension       Date:  2011-03-07       Impact factor: 10.190

3.  Use of multiple biomarkers to improve the prediction of death from cardiovascular causes.

Authors:  Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

4.  Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease.

Authors:  M Adnan Nadir; Sushma Rekhraj; Li Wei; Tiong K Lim; John Davidson; Thomas M MacDonald; Chim C Lang; Ellie Dow; Allan D Struthers
Journal:  J Am Coll Cardiol       Date:  2012-08-22       Impact factor: 24.094

Review 5.  B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.

Authors:  Emanuele Di Angelantonio; Rajiv Chowdhury; Nadeem Sarwar; Kausik K Ray; Reeta Gobin; Danish Saleheen; Alexander Thompson; Vilmundur Gudnason; Naveed Sattar; John Danesh
Journal:  Circulation       Date:  2009-11-16       Impact factor: 29.690

6.  N-terminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease.

Authors:  S Goya Wannamethee; Paul Welsh; Gordon D Lowe; Vilmundur Gudnason; Emanuele Di Angelantonio; Lucy Lennon; Ann Rumley; Peter H Whincup; Naveed Sattar
Journal:  J Am Coll Cardiol       Date:  2011-06-28       Impact factor: 24.094

Review 7.  High B-Type Natriuretic Peptide Hypertensives at Target Blood Pressure: Potential Role of β-Blockers to Reduce Their Elevated Risk.

Authors:  Allan D Struthers; Jacob George
Journal:  Hypertension       Date:  2015-09-21       Impact factor: 10.190

8.  N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.

Authors:  Anna H Price; Paul Welsh; Christopher J Weir; Insa Feinkohl; Christine M Robertson; Joanne R Morling; Stela McLachlan; Mark W J Strachan; Naveed Sattar; Jackie F Price
Journal:  Diabetologia       Date:  2014-09-18       Impact factor: 10.122

9.  Ruling out cardiac failure: cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography.

Authors:  Maria-José Ferrandis; Ingvar Ryden; Tomas L Lindahl; Anders Larsson
Journal:  Ups J Med Sci       Date:  2012-12-12       Impact factor: 2.384

10.  The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Authors:  Paul Welsh; Neil R Poulter; Choon L Chang; Peter S Sever; Naveed Sattar
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

View more
  3 in total

1.  Sacubitril/valsartan: a cardiovascular drug with pluripotential actions.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

2.  Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.

Authors:  Steven G Chrysant
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-01-16       Impact factor: 3.738

3.  N-Terminal Pro-B-Type Natriuretic Peptide and Longitudinal Risk of Hypertension.

Authors:  Charles D Nicoli; Timothy B Plante; D Leann Long; Suzanne E Judd; Leslie A McClure; Pankaj Arora; Mary Cushman
Journal:  Am J Hypertens       Date:  2021-05-22       Impact factor: 2.689

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.